ImmunityBio
IBRX
61 hedge funds and large institutions have $9.95M invested in ImmunityBio in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 11 closing their positions.
26% more call options, than puts
Call options by funds: $48K | Put options by funds: $38K
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
0% more funds holding
Funds holding: 61 → 61 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
2.76% less ownership
Funds ownership: 13.59% → 10.83% (-2.8%)
75% less capital invested
Capital invested by funds: $39.8M → $9.95M (-$29.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$862K |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$532K |
| 3 |
D.E. Shaw & Co
New York
|
+$319K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$309K |
| 5 |
HK
Horizon Kinetics
New York
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$9.85M |
| 2 |
BlackRock
New York
|
-$1.87M |
| 3 |
ProShare Advisors
Bethesda,
Maryland
|
-$132K |
| 4 |
Bank of New York Mellon
New York
|
-$111K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$101K |
IBRX Hedge Fund Activity: Q4 2018 in Review
61 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2018, worth a combined $9.95M — down 75% from $39.8M a quarter earlier.
Fund positioning in IBRX was balanced in Q4 2018: 11 funds opened new positions, 11 closed out, 22 added to existing stakes and 18 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $862K. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $9.85M sold.
- 61 institutional investors held ImmunityBio (IBRX) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $9.95M of ImmunityBio stock for Q4 2018, down 75% quarter-over-quarter.
- 11 funds opened new ImmunityBio positions in Q4 2018 and 11 closed out, a net change of 0 holders.
- The largest ImmunityBio buyer in Q4 2018 was Renaissance Technologies, an estimated $862K added.
- The largest ImmunityBio seller in Q4 2018 was Capital Research Global Investors, an estimated $9.85M sold.
Based on aggregated 13F filings for Q4 2018.